VolitionRX Ltd
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $7.3M
- Price
- $0.2429
- % Change (Daily % change from the live per-ticker quote feed.)
- +4.70%
- Volume
- 644.3K
About
VolitionRx Limited, a multi-national epigenetics company, develops blood tests to help detect and monitor a range of cancers, and diseases associated with NETosis in the United States, Europe, and Asia. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets, detects diseases associated with NETosis, such as sepsis; Nu.Q Discover, a solution to profiling nucleosomes. It also provides Nu.Q Cancer for predicting treatment response, monitoring treatment response and disease progression, and amending a patient's cancer treatment regimen; and Capture-PCR and Capture-Seq, which are isolating and capturing circulating tumor-derived DNA from plasma samples for early cancer detection. VolitionRx Limited is headquartered in Henderson, Nevada.
Quick stats
Shares outstanding30.1M
Computed float29.6M
Float / shares98.4%
Key info
SectorHealthcare
IndustryMedical - Devices
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0000093314
Websitehttps://volition.com
AI Summary
AI-generated1/47
minorbullishpartnership
VolitionRx Shares Further Details and Video of the DETECSEPS Program Launch in France
VolitionRx shared further details and video of the official launch of the DETECSEPS program in France, a government-funded consortium focused on early detection of sepsis in emergency-department patients with suspected infection.
The project, a winner of the French Health Innovation Agency's 'Challenge Prevention' call operated by the Banque Publique d'Investissement under the France 2030 plan, carries €6.3 million (~$7.3 million) in government funding and will evaluate the strategy in 1,000 patients across AP-HP and Hospices Civils de Lyon emergency departments.
Volition is the consortium's sole biomarker provider, supplying its Nu.Q® NETs H3.1 test pro-bono, while IDS France (part of Revvity) provides the i10 automated analyzer that runs the biomarker alongside the NEWS2 clinical score.
CEO Cameron Reynolds called the launch an exceptional vote of confidence in the Nu.Q® NETs platform; the participation is pro-bono with no direct revenue, but a conclusive readout could support large-scale deployment of the sepsis test in care pathways.
Red flags
- Volition supplies the Nu.Q® H3.1 Assay pro-bono — no direct revenue from the program
- Volition's share of the €6.3 million funding is not disclosed; funding flows to the consortium
- Commercial upside depends on a conclusive readout of the 1,000-patient evaluation; no timeline for results is provided